AT1 receptors mediate angiotensin II uptake and transport by brain microvessel endothelial cells in primary culture by Rose, Jayna M. & Audus, Kenneth L.
Rose, J.M. and Audus, K.L. (1999) AT1 receptors mediate angiotensin II uptake and transport by brain microvessel endothelial 
cells in primary culture. J. Cardiovasc. Pharmacol. 33, 30-35.  PMID: 9890393. 
Publisher’s official version: 
http://journals.lww.com/cardiovascularpharm/Fulltext/1999/01000/AT1_Receptors_Mediate_Angiotensin_II_Uptake_and.5.aspx .  
Open Access version:  http://kuscholarworks.ku.edu/dspace/. 
1 
 
P
le
a
se
 n
o
te
 t
h
a
t 
th
is
 is
 a
n
 a
u
th
o
r-
p
ro
d
u
ce
d
 P
D
F 
o
f 
a
n
 a
rt
ic
le
 a
cc
ep
te
d
 f
o
r 
p
u
b
lic
a
ti
o
n
 f
o
llo
w
in
g
 p
ee
r 
re
vi
ew
. T
h
e 
p
u
b
lis
h
er
 v
er
si
o
n
 is
 a
va
ila
b
le
 o
n
 it
s 
si
te
.  
 [This document contains the author’s accepted manuscript.  For the publisher’s version, see the link in 
the header of this document.] 
 
Paper citation:   
Rose, J.M. and Audus, K.L. (1999) AT1 receptors mediate angiotensin II uptake and transport by brain 
microvessel endothelial cells in primary culture. J. Cardiovasc. Pharmacol. 33, 30-35.  PMID: 9890393 
 
Keywords: 
Angiotensin II, Angiotensin receptor antagonists, Blood-brain barrier, Brain microvessel endothelial cells, 
losartan, PD 123,319 
 
Abstract: 
The endothelial lining of the blood-brain barrier tightly controls the distribution of peptide 
hormones between the central nervous system and the circulation.  Using primary cultures of brain 
microvessel endothelial cells, an in vitro model of the blood-brain barrier,  we report here the uptake 
and transport of the octapeptide angiotensin II by a specific receptor population.  Using the angiotensin 
II antagonists losartan (AT1 specific) and PD 123,319 (AT2 specific) we have shown that both the uptake 
and transport of angiotensin II were mediated by the AT1 receptor.  Western blot analysis confirmed the 
existence of the AT1 receptor in our cell culture model.  Rhodamine 123 studies also suggested that both 
angiotensin II antagonists, but not angiotensin II, were substrates for the P-glycoprotein efflux system 
thus restricting the transport of these compounds.  These results suggest an AT1 receptor mediates 
uptake and transport of angiotensin II at the blood-brain barrier and may contribute to the regulation of 
cerebrovascular levels of the peptide. 
Text of paper: 
 
Introduction 
The octapeptide angiotensin II produces a number of physiological actions, the most common of these 
being its peripheral role as a potent vasoconstrictor (1).  The renin angiotensin system is also known to 
exist in the brain (1-3).  Brain angiotensin II appears to function in the central regulation of blood 
pressure, the regulation of body fluid volume, and the control of hormone release (4).  Angiotensin II 
does not readily penetrate the blood-brain barrier (BBB) and the effects of angiotensin II are generally 
considered to be mediated by receptors in the circumventricular regions of the brain which lack the BBB. 
Speth and Harik (5) and Grammas et al. (6) observed that there were angiotensin II receptor binding 
sites on the brain microvessel endothelial cells (BMECs) lining the BBB and that these binding sites have 
biological activity (7,8).  Subsequently, studies by Guillot and Audus reported that there were specific 
angiotensin II binding sites on BMECs in primary culture and that the cells internalized the peptide (9).  
Angiotensin II receptors are also found on peripheral vascular endothelial cells and mediate 
transendothelial transport of the peptide (10).  The subtyping of these binding sites, however, has not 
been reported. 
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There are two major subtypes of angiotensin II receptors known to exist, designated AT1 and AT2.  Both 
receptor subtypes have been found in brain tissue of rats, monkeys, and humans.  Most of the known 
actions of angiotensin II are mediated through the AT1 receptor (11).  The development of nonpeptide 
antagonists has made it possible to distinguish between the two receptor subtypes.  Losartan is a highly 
specific nonpeptide AT1 antagonist and PD 123,319 is a highly specific nonpeptide AT2 antagonist.  These 
antagonists lack the partial agonist activities of peptide angiotensin II analogs, allowing study of 
angiotensin II processing without interfering side effects (11). 
The objective of this study was to use primary cultures of BMECs to reveal the receptor subtype 
populations that regulate angiotensin II uptake and distribution across the BBB.  The nonpeptide 
antagonists losartan and PD 123,319 were used in this study to distinguish the AT1 and AT2 receptor 
subtypes on BMECs.  The definition of receptor subtypes providing for the clearance of peptides at the 
BBB contributes to our knowledge of fundamental physiological mechanisms regulating cerebrovascular 
levels of vasoeffectors.  In addition, characterization of BBB carrier mechanisms potentially can provide 
physiological strategies to beneficially circumvent this barrier by covalently linking pharmacophores to 
receptor ligands known to be transported across the barrier (12). 
 
Materials and methods 
Materials 
[3H]-angiotensin II (specific activity 45 Ci/mmol) was purchased from Amersham (Arlington Heights, IL).   
Losartan was donated by Merck & Co. (Rahway, NJ) and PD 123,319 ditrifluoroacetate was purchased 
from Research Biochemicals International (Natick, MA).  Cyclosporin A was purchased from Sigma 
Chemical Company (St. Louis, MO).  The AT1 (N-10) rabbit polyclonal antibody was purchased from Santa 
Cruz Biotechnology, Inc. (Santa Cruz, CA).  All other compounds used were of the highest commercially 
available quality. 
Cell Culture 
Bovine brain microvessel endothelial cells (BMECs) were isolated from gray matter of cerebral cortices 
by enzymatic digestion and subsequent centrifugation, and seeded into primary culture as detailed by 
Audus and Borchardt (13,14).  This preparation has been extensively characterized as reported in the 
literature (13,15-18).  Isolated BMECs were seeded at a density of 50,000 cells/cm2 into 12-well plates 
and 100 mm tissue culture dishes (Corning Costar Corporation, Cambridge, MA), pretreated with rat-tail 
collagen and bovine fibronectin (Sigma Chemical Co.) in a culture medium consisting of 45 % minimum 
essential medium, 45 % F-12 Ham nutrient mixture (Gibco Life Technologies, Grand Island, NY), 10 mM 
HEPES, pH 7.4, 13 mM sodium bicarbonate, 10 % plasma-derived equine serum, 100 g/ml heparin, 100 
g/ml streptomycin, 100 g/ml penicillin G, 50 g/ml polymyxin B, and 2.5 g/ml amphotericin B (Sigma 
Chemical Co.).  The cells were cultured at 37C with 95 % humidity and 5 % CO2.  Cells were fed on the 
third day after seeding and then every two days until confluent monolayers were formed (10-14 days). 
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Binding and internalization studies 
The effect of the nonpeptide antagonists on [3H]-angiotensin II binding and internalization was studied 
in 12-well plates at 37C.  Aliquots of specified concentrations of losartan and PD 123,319 dissolved in 
culture medium, containing equine serum, were added to each well with a pulse of [3H]-angiotensin II.  
The plates were incubated for 30 minutes at 37C.  At the conclusion of the experiment, the medium 
was aspirated from each well and the wells were rinsed three times with ice cold culture medium.  The 
cell monolayers were then solubilized by the addition of 1.0 ml of 0.2 N NaOH / 0.5 % Triton X-100.  An 
aliquot of 100 l was removed to analyze protein content using the BCA protein assay kit (Pierce, 
Rockford, IL).  The remaining lysate from each well was collected, placed in a scintillation vial with 10 ml 
of scintillation cocktail, and assayed with a Beckman LS 6800 scintillation counter. 
Rhodamine 123 uptake studies were also performed on confluent monolayers in 12-well plates.  
Angiotensin II, losartan, PD 123,319, or cyclosporin A dissolved in culture medium was added to each 
well and the plate was preincubated for one hour at 37C.  After the one hour preincubation, rhodamine 
123 was added to each well for a final concentration of 5 M, and the plate was incubated at 37C for 
an additional hour.  After the second incubation, the plate was rinsed and the monolayers were 
solubilized as described above.  The contents of each well were collected into cuvettes and assayed by 
fluorescence using an SLM-Aminco 4800 fluorometer (ex = 500 nm, em = 550 nm).  After measuring 
relative fluorescence, 100 l was removed from each cuvette and assayed for protein content with the 
BCA protein assay kit (Pierce). 
Transendothelial permeability studies 
Polycarbonate membranes (pore size 0.4 m) were placed into 100 mm tissue culture dishes and coated 
with rat-tail collagen and bovine fibronectin.  BMECs were grown to confluent monolayers as 
determined by inspection of the areas around the membranes using an inverted microscope.  The 
basolateral side of the cells was defined as the side facing the collagen matrix.  Once confluent 
monolayers were formed, the membranes were carefully placed into a horizontal Side-bi-Side 
diffusion apparatus (Crown Glass, Inc., Somerville, NJ) for transendothelial permeability studies.  The 
area of the diffusion membrane was 0.636 cm2.  The donor and receiver chambers were filled with 3.0 
ml culture medium, containing equine serum, and the temperature was maintained at 37C with an 
external circulating water bath.  The contents of each chamber were stirred with Teflon coated magnetic 
stir bars at a speed of 600 r/min driven by an external drive console (Crown Glass, Inc.).  The apical to 
basolateral transport of a pulse of [3H]-angiotensin II was studied for 30 minutes.  An aliquot of 25 l 
was removed from the donor chamber to be assayed for initial donor concentration.  Sample aliquots of 
100 l were removed from the receiver chamber at various intervals.  Following the 30 minute receiver 
sampling time, different concentrations of losartan or PD 123,319 were added to the donor chamber.  
Receiver samples were then taken for an additional 60 minutes.  After each receiver sample, the volume 
was replaced with fresh medium.  The samples were placed in a scintillation vial with 10 ml of 
scintillation cocktail and assayed by scintillation spectrometry.  The flux was determined by plotting 
pmoles vs. minutes for each sampling interval (0-30 minutes and 30-90 minutes).  The apparent 
permeability coefficient was calculated using the equation: 
P = Flux / (A*CDo) 
where flux is the slope of each line, A is the area of the membrane, and CDo is the initial donor 
concentration.  The donor concentration did not change by more than 10 % during the time period of 
these experiments. 
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Western blot 
Total cellular extract was prepared using confluent monolayers of BMECs.  The cells were lysed with a 45 
min incubation in ice-cold phosphate buffer saline containing 3 % sodium dodecyl sulfate (SDS) and 
protease inhibitors (0.1mM leupeptin, 73 M pepstatin A, and 100 g/ml PMSF).  The cell lysate was 
then centrifuged at 12,000 g for 15 min and the supernatant containing solubilized membrane proteins 
was stored at -20C and used for further analysis.  Total cell protein was measured by the Micro BCA 
protein assay (Pierce) using bovine serum albumin as a standard.  Cell plasma membranes were 
prepared using confluent monolayers of BMECs.  The cells were removed from the tissue culture plates 
with a trypsin / EDTA solution.  The cell suspension was then diluted in 5 volumes of ice-cold 10 mM Tris 
- HCl, 0.1 mM EDTA, pH 7.5 (TE buffer) and homogenized.  The homogenate was passed through a fine-
gauge syringe needle and then centrifuged at 500 g for 15 minutes to pellet unbroken cells and nuclei, 
leaving a membrane containing supernatant.  The plasma membranes were collected by centrifugation 
at 40,000 g for 60 minutes.  The pellets were washed in 10 volumes of TE buffer and re-centrifuged at 
40,000 g for 60 minutes.  The pellets were resuspended in TE buffer and stored at -70C (19).  The 
protein concentration was measured by the Micro BCA protein assay (Pierce) using bovine serum 
albumin as a standard.  Cell proteins were electrophoresed on a 10 % Tris-Glycine gel (NOVEX, San 
Diego, CA) and transferred to a PVDF membrane.  Immunoreactive protein was detected with the AT1 
polyclonal antibody using the enhanced chemiluminescence method (ECL) as per the manufacturer’s 
protocol (Amersham, Downers Grove, IL).  A positive control peptide (Santa Cruz Biotechnology, Inc.) 
and a negative control (serum albumin) were used to establish and confirm blot conditions. 
Statistical analysis 
The comparison between mean values within each experimental series was performed by one-way 
analysis of variance using Dunnett’s test to compare several treatments against a control. 
 
Results 
The temperature and concentration dependence of the binding and internalization kinetics for 
angiotensin II were described in an earlier report (9).  In this study, the uptake of [3H]-angiotensin II 
alone and with different concentrations of losartan is shown in Fig. 1.  When coincubated for 30 minutes 
at 37C, micromolar concentrations of losartan were observed to significantly inhibit the binding and 
uptake of [3H]-angiotensin II.  In Fig. 2 the effect of PD 123,319 ditrifluoroacetate on angiotensin II 
uptake is shown.  When different concentrations of PD 123,319 were coincubated with [3H]-angiotensin 
II for 30 minutes, there was no significant change in the amount of angiotensin II taken up by the cells. 
Since the concentrations of losartan required to inhibit angiotensin II binding and internalization were 
higher than expected and that earlier studies suggested a role for P-glycoprotein in mediating losartan 
distribution across the BBB (20), we performed rhodamine 123 uptake studies.  The uptake of 
rhodamine 123 alone and with angiotensin II,  losartan, PD 123,319, and cyclosporin A is shown in Fig. 3.  
The cells were exposed for one hour with 100 M angiotensin II, 750 M losartan, 500 M PD 123,319, 
or 1 g/ml cyclosporin A.  After the one hour incubation, 5 M rhodamine 123 was added to each well 
and the cells were incubated another hour.  As shown in Fig. 3, losartan, PD 123,319, and cyclosporin A 
significantly increased the uptake of rhodamine 123 in BMECs, indicating that only the nonpeptide 
antagonists interact with P-glycoprotein. 
  
Rose, J.M. and Audus, K.L. (1999) AT1 receptors mediate angiotensin II uptake and transport by brain microvessel endothelial 
cells in primary culture. J. Cardiovasc. Pharmacol. 33, 30-35.  PMID: 9890393. 
Publisher’s official version: 
http://journals.lww.com/cardiovascularpharm/Fulltext/1999/01000/AT1_Receptors_Mediate_Angiotensin_II_Uptake_and.5.aspx .  
Open Access version:  http://kuscholarworks.ku.edu/dspace/. 
5 
 
The permeation of angiotensin II across BMECs was found to increase linearly over time as shown in Fig. 
4 at 37C.  The transport of a pulse of [3H]-angiotensin II was monitored alone for 30 minutes before 
addition of the antagonists.  The effect of losartan on angiotensin II transport is shown in Fig. 5 where 
again, micromolar concentrations of losartan were found to significantly decrease the transport of [3H]-
angiotensin II.  There was no decrease in angiotensin II transport seen with PD 123,319 as shown in Fig. 
6. 
Western blot studies, shown in Fig. 7A and 7B, were generated using an AT1 receptor polyclonal 
antibody and show that the AT1 receptor is present in BMECs.  Fig. 7A shows the western analysis of 
total cell lysate and Fig. 7B shows the blot of BMEC membranes compared to total cell lysate.  The blots 
indicated that there was a greater concentration of AT1 receptors in the membrane portion of the cells. 
 
Discussion 
 Speth and Harik (5) and Grammas et al. (6) originally described the presence of specific angiotensin 
II binding sites on brain microvessels.  A hypothesis developed that angiotensin binding sites in the 
cerebrovasculature regulated water and ion transport (7,8).  Guillot and Audus subsequently described 
angiotensin II binding sites on primary cultures of bovine BMECs, a well-characterized in vitro system 
representing BBB endothelium.  Scatchard analysis of the concentration-dependent binding of 
angiotensin II to BMECs revealed a single population of binding sites with an apparent Kd of 3.1 nM (9).  
In addition, angiotensin II was observed to be internalized intact by BMECs and apical application of the 
peptide regulated permeability properties of the BMEC monolayers at concentrations similar to the 
binding site affinity (9,21).  The latter findings have been recently confirmed by other researchers in 
human brain microvessel endothelial cells (22). 
 In this study, we have shown that the binding and uptake of angiotensin II by BMECs was inhibited 
by losartan, the AT1 receptor antagonist and not the AT2 antagonist, PD 123,319.  This observation was 
consistent with the presence of a single population of angiotensin II binding sites that were described by 
Guillot and Audus (9).  Therefore, it appears that an AT1 receptor mediates clearance of angiotensin II by 
BMECs.  Although our data includes both binding and internalization, the concentrations at which an 
antagonist was inhibitory were higher than expected based on other receptor studies (11) and our 
observation that specific binding of angiotensin II to bovine BMECs could be inhibited by nM 
concentrations of peptide analogs, saralasin and sarathrin (9). 
 Our earlier studies on the uptake and transport of losartan itself indicated that the compound was 
an apparent substrate for P-glycoprotein at submicromolar concentrations (20).  Therefore, P-
glycoprotein may be a competing mechanism for losartan interactions with the BMEC membrane.  To 
determine if the antagonists and angiotensin II were potential substrates for P-glycoprotein, the uptake 
studies were performed with rhodamine 123, a specific substrate for the P-glycoprotein efflux pump 
(23-26).  The uptake of rhodamine 123 alone and with pretreatment of the monolayers using 
angiotensin II, losartan, PD 123,319, or a positive control, cyclosporin A (26), suggested that both 
antagonists were inhibitors of P-glycoprotein.  Angiotensin II does not affect rhodamine 123 uptake, 
therefore it appears that the nonpeptide antagonists may not be as effective in blocking BMEC uptake 
and binding due to their added affinity for P-glycoprotein.  On the other hand, the micromolar 
concentrations used here remain within the concentration range of losartan antagonist activity across a 
variety of different species, tissue types, and angiotensin II mediated biological functions (27). 
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 Angiotensin II was previously shown to be transported across arterial endothelial cell monolayers by 
a specific, saturable mechanism that could be inhibited by unlabeled peptide.  Mineo et al. required 
micromolar concentrations of angiotensin to inhibit arterial endothelial cell transport of the 
radiolabeled angiotensin II (10).  We have observed that angiotensin II crosses monolayers of BMECs 
intact (28,29) at a rate slightly higher than expected based on its molecular weight.  The transport was 
also a saturable process, Km 1.7 nM, and angiotensin II transport from the apical to the basolateral side 
was greater than the reverse direction (28,30).  In the present study, the differential effects of the two 
angiotensin II receptor antagonists on the passage of the peptide through monolayers of BMECs 
affirmed the role of an AT1 mediated mechanism with losartan inhibiting the transport of angiotensin II. 
As observed in the uptake studies, the AT2 antagonist effect on angiotensin II transport was also absent.  
Consistent with the uptake studies, micromolar concentrations of losartan were required to inhibit 
angiotensin transport. 
 The AT1 receptor belongs to the class of G-protein-coupled seven-transmembrane receptors and is 
made up of 359 amino acids with an unmodified molecular weight of 41,000 (11).  Using western blot 
analysis we confirmed the expression of the AT1 receptor in BMECs.  Further, we demonstrated that the 
AT1 receptor resides in the membrane portion of BMECs.  The AT1 receptor is responsible for most of the 
known biological effects of angiotensin II, including those of the central nervous system (11,31).  
Therefore, expression in the BMECs was consistent with most other angiotensin II mediated functions.  
At the time of this study, antibodies for the AT2 receptor were not available to potentially rule out 
expression of this class of receptors in BMECs. 
 In addition to peripheral endothelia (10), other cell types have been shown to internalize 
angiotensin II including adrenocortical cells (32) and vascular smooth muscle cells (33,34).  Our results 
suggest that the presence of the AT1 receptor populations mediating BMEC uptake and transport of 
angiotensin II may serve as a local physiological mechanism for controlling angiotensin II distribution in 
the cerebrovasculature.  This observation appears consistent with the local control of the renin-
angiotensin systems associated with specific tissues (1-3).  Alternatively, the AT1 receptors might provide 
a mechanism that could be exploited for facilitating delivery of some substances via chimeric constructs 
into the central nervous system like other endogenous peptides, insulin and transferrin (35,36).  
However, like insulin, it is also apparent that angiotensin II has significant biological activity at the BBB, 
regulating the BMEC secretion of other vasoeffectors (9,21,22,37) and the permeability properties of the 
cells (7-9) that would preclude its use in chimeric constructs.  The nonpeptide antagonists such as 
losartan could provide alternative targeting ligands in a chimeric construct; unfortunately, losartan 
appears to be a substrate for BMEC efflux mechanisms (20).  Therefore, future works in our laboratory 
will focus on the transport of alternative ligands for the carrier, including metabolically stable 
angiotensin II peptide analogs. 
 In summary, we have shown that the uptake and transport of angiotensin II by BMECs appears to be 
mediated by the AT1 receptor.  These results form a better understanding of the regulation of 
cerebrovascular levels of angiotensin II by the BBB and may lead to possible delivery strategies for 
therapeutic chimeric peptides. 
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Figure Legends 
Figure 1.  Angiotensin II uptake (pulse of [3H]-angiotensin II) in BMECs alone (shaded bar) and in the 
presence of losartan (hatched bars) for 30 minutes at 37C, pH 7.4.  Each bar represents the mean  SD 
of n = 3.  * represents statistically significant changes (P < 0.05). 
 
Figure 2.  Angiotensin II uptake (pulse of [3H]-angiotensin II) in BMECs alone (shaded bar) and in the 
presence of PD 123,319 (hatched bars) for 30 minutes at 37C, pH 7.4.  Each bar represents the mean  
SD of n = 3. 
 
Figure 3.  Percentage of rhodamine 123 (initial concentration 5 M) uptake in BMECs alone (shaded bar) 
and after 60 min pretreatment of the monolayers with 100M angiotensin II, 750 M losartan, 500 M 
PD 123,319, or 1 g/ml cyclosporin A (hatched bars).  Each bar represents the mean  SD of n = 3.  ** 
represents statistically significant changes (P < 0.01). 
 
Figure 4.  Transport of [3H]-angiotensin II was studied alone for 30 minutes.  After the 30 minute 
sampling, the receptor antagonist was added to the donor chamber.  Flux was calculated for each set of 
sampling based on the slope of the line. 
 
Figure 5.  Apparent permeability coefficients for a pulse of [3H]-angiotensin II across BMECs at 37C 
alone (shaded bar) and in the presence of losartan (hatched bars).  Each bar represents the mean  SD 
of n = 3.  * represents statistically significant changes (P < 0.05), ** represents statistically significant 
changes (P < 0.01). 
 
Figure 6. Apparent permeability coefficients for a pulse of [3H]-angiotensin II across BMECs at 37C 
alone (shaded bar) and in the presence of PD 123,319 (hatched bars).  Each bar represents the mean  
SD of n = 3. 
 
Figure 7.   A)  Immunoblot analysis of AT1 receptor (MW 41,000) expression in total BMEC lysate.  B)  
Immunoblot analysis of AT1 receptor (MW 41,000) expression in BMEC membranes and total BMEC 
lysate (*). 
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